Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Part of Head and Neck Cancer

21 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Head and Neck Squamous Cell Carcinoma

77 trials tracked for Head and Neck Squamous Cell Carcinoma: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 803 citations.

77Trials tracked
9Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 8 Phase 2 60 Phase 1 6 Other / NA 2
  1. Phase 3 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed · 803 cited
  2. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) Completed · 81 cited
  3. Phase 3 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Completed · 54 cited
  4. Phase 3 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Completed · 18 cited
  5. Phase 4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed
  6. Phase 3 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
Show 44 more trials
  1. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension Completed
  2. Phase 3 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed
  3. Phase 3 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed
  4. Phase 2 Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma Completed
  5. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  6. Phase 2 De-Escalation Therapy for Human Papillomavirus Negative Disease Completed
  7. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  8. Phase 2 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) Completed
  9. Phase 2 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma Completed
  10. Phase 2 A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients Completed
  11. Phase 2 Preoperative Treatment With Cetuximab and/or IMC-A12 Completed
  12. Phase 2 Expansion Trial for Axitinib In Head And Neck Cancer Completed
  13. Phase 2 Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients Completed
  14. Phase 2 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Completed
  15. Phase 2 Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer Completed
  16. Phase 2 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Completed
  17. Phase 2 Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer Completed
  18. Phase 2 IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC Completed
  19. Phase 2 ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma Completed
  20. Phase 2 Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Completed
  21. Phase 2 Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Completed
  22. Phase 2 Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma Completed
  23. Phase 2 Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer Completed
  24. Phase 2 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer Completed
  25. Phase 2 Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Completed
  26. Phase 2 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed
  27. Phase 2 Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer Completed
  28. Phase 2 Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Completed
  29. Phase 2 Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer Completed
  30. Phase 2 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract Completed
  31. Phase 2 Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) Completed
  32. Phase 2 Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) Completed
  33. Phase 2 Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy Completed
  34. Phase 2 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Completed
  35. Phase 2 Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma Completed
  36. Phase 2 Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer Completed
  37. Phase 2 IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma Completed
  38. Phase 2 Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients Completed
  39. Phase 2 Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma Completed
  40. Phase 2 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck Completed
  41. Phase 2 Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck Completed
  42. Phase 2 Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Completed
  43. Phase 2 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer Completed
  44. Phase 2 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck Completed

Showing the 50 most-cited and recently-updated of 77 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Head and Neck Squamous Cell Carcinoma: what the trials found

Several immunotherapies have been evaluated for Head and Neck Squamous Cell Carcinoma. Nivolumab demonstrated a statistically significant improvement in Overall Survival (OS) compared to the control group (p=0.0101) 11. Additionally, Pembrolizumab was evaluated across multiple trials; one study reported a 2-year Progression-free Survival (PFS) of 75.5% 3, and other studies confirmed its use in various cohorts [7, 20].

Lenvatinib showed significant improvements in Objective Response Rate (ORR) (p=0.0000019) 12 and Progression Free Survival (PFS) (p=0.0000037) 15 compared to standard treatments, although the difference in Overall Survival was not statistically significant in these trials [12, 15].

Cetuximab has been studied both as a monotherapy and in combination with radiotherapy; while it showed some efficacy, results for Progression-free Survival (p=0.8878) and Overall Survival (p=0.8175) did not reach statistical significance 13. A separate trial evaluating Cetuximab plus concomitant boost radiotherapy was also conducted [17, 18].

Alternative radiation modalities include stereotactic body radiotherapy 10, while the use of MEDI4736 in combination with Tremelimumab or as monotherapy did not show statistically significant differences in Overall Survival compared to standard of care in specific PD-L1 high subgroups 14.

Recent results — preliminary, needs further review

  • Pembrolizumab showed a median Overall Survival of 14.9 months and a progression-free survival rate of 12% vs 7% in a small cohort 19.
  • Atezolizumab was associated with a 50.0% Pathologic Complete Response (pCR) rate compared to 16.7% in a small study, with no Grade 3 or higher immune-related adverse events reported 21.
  • Cisplatin treatment resulted in adverse event rates ranging from 21.9% to 38.5% across various categories 5.
  • Intensity modulated radiation therapy (IMRT) was associated with specific quality of life scores across several functional subscales 6.
  • Other recent investigations include paclitaxel/carboplatin 1, IO102-IO103 in combination with pembrolizumab 4, Nivolumab+Relatlimab 8, L-NMMA 9, and IPI-549 22.

For the clinician treating this condition

  • Nivolumab is associated with a statistically significant improvement in Overall Survival compared to standard treatments.
  • Lenvatinib provides significant improvements in Objective Response Rate (ORR) and Progression Free Survival (PFS), though it did not significantly impact Overall Survival in the studied cohorts.
  • Atezolizumab showed a high rate of Pathologic Complete Response (pCR) in a small cohort without reported high-grade immune-related adverse events.

AI synthesis of 16 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Oncology RCT
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…
Jul 27, 2026
High tumor mutational burden correlates with improved objective response rate in HNSCC patients
ENT (Otolaryngology) Meta-analysis
High tumor mutational burden correlates with improved objective response rate in HNSCC patients High tumor mutation burden predicts better results in head cancer
This meta-analysis of 1472 patients with head and neck squamous cell carcinoma (HNSCC) found that high tumor mutational burden (TMB) is asso…
A high number of mutations in a tumor may help doctors predict which patients will respond best to immunotherapy.
Jul 25, 2026
Combination Therapies Improve Progression Free Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ENT (Otolaryngology) Meta-analysis
Combination Therapies Improve Progression Free Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Combination therapies show promise for advanced head and neck cancer
This meta-analysis evaluated combination therapies involving targeted agents or immunotherapy with chemotherapy for patients with recurrent …
Combining immunotherapy or targeted drugs with chemotherapy may help patients with advanced head and neck cancer live longer without the dis…
Jul 25, 2026
Early recognition of femoral metastasis in HNSCC is essential to facilitate timely palliative intervention
Oncology Meta-analysis
Early recognition of femoral metastasis in HNSCC is essential to facilitate timely palliative intervention New data reveals management of head and neck cancer spread
This systematic review characterizes clinical features and management outcomes for patients with head and neck squamous cell carcinoma (HNSC…
Identifying how head and neck cancer spreads to the femur can help doctors provide better care and improve quality of life for patients.
Frontiers Jul 7, 2026
Pretreatment CPS and HPV status correlate with pathological response in neoadjuvant immunotherapy for LAHNSCC
Oncology Meta-analysis
Pretreatment CPS and HPV status correlate with pathological response in neoadjuvant immunotherapy for LAHNSCC Certain markers may predict how well immunotherapy treats head cancer
This meta-analysis of 26 studies involving 980 patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) found that hig…
New data suggests that specific biological markers can help doctors predict how well a patient's tumor will respond to immunotherapy.
NEJM Jun 29, 2026
HOX gene dysregulation influences cellular processes but currently lacks utility as reliable HNSCC biomarkers
Oncology Sys. Review
HOX gene dysregulation influences cellular processes but currently lacks utility as reliable HNSCC biomarkers HOX genes play complex roles in head and neck cancer
This mini-review examines the role of HOX genes in head and neck squamous cell carcinoma (HNSCC). The authors conclude that while these gene…
New research highlights how HOX genes drive tumor growth and survival in head and neck cancers, though their use as clinical tools is still …
Frontiers Jun 16, 2026
Local brain therapies associated with reduced mortality in HNSCC patients with brain metastasis
Oncology Cohort
Local brain therapies associated with reduced mortality in HNSCC patients with brain metastasis Local brain treatments linked to modest survival gains in rare head and neck cancer cases
This retrospective cohort analysis evaluated 201 patients with head and neck squamous cell carcinoma and brain metastasis from three tertiar…
Local brain treatments linked to lower death risk for rare head and neck cancer patients who develop brain metastases, though most still die…
Frontiers Jun 4, 2026
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Oncology Phase I
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study. Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Jun 4, 2026
20-fraction hypofractionated radiotherapy passes noninferiority for tumor control and late toxicity in locally advanced head and neck cancer
Drug Pipeline RCT
20-fraction hypofractionated radiotherapy passes noninferiority for tumor control and late toxicity in locally advanced head and neck cancer Shorter radiation schedule works as well for head and neck cancer
This randomized, open-label, Phase 3 noninferiority trial enrolled 792 patients with locally advanced head and neck squamous cell carcinoma …
A shorter radiation plan for head and neck cancer showed the same effectiveness as a longer schedule while reducing late side effects.
Jun 1, 2026
Systematic review and meta-analysis on immunotherapy for head and neck squamous cell carcinoma
Oncology Meta-analysis
Systematic review and meta-analysis on immunotherapy for head and neck squamous cell carcinoma Immunotherapy helps advanced head and neck cancer patients live longer
This systematic review and meta-analysis synthesized evidence on immunotherapy for head and neck squamous cell carcinoma. The authors report…
New analysis shows immune therapy helps advanced head and neck cancer patients survive longer when combined with other treatments
Frontiers May 15, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Meta-analysis finds BCI_net prognostic for overall survival in oral squamous cell carcinoma
Oncology Meta-analysis
Meta-analysis finds BCI_net prognostic for overall survival in oral squamous cell carcinoma A new cancer test reads tumor cell chats to predict survival
This meta-analysis of 2 cohorts (TCGA-HNSC n=519, GSE65858 n=270) found that the BCI_net directional composite was independently associated …
Your cancer cells may be chatting with each other, and a new test that listens to those conversations could predict how aggressive the disea…
medRxiv May 12, 2026

Research across Head and Neck Cancer

Related studies from across the Head and Neck Cancer family.

Immunonutrition may improve management of radiation-induced oral mucositis in head and neck cancer patients
Allergy & Immunology Sys. Review
Immunonutrition may improve management of radiation-induced oral mucositis in head and neck cancer patients Immunonutrition may help manage mouth sores in head and neck cancer
This narrative review examines the role of immunonutrition for managing oral mucositis in patients with head and neck malignancies undergoin…
Patients with head and neck cancer often suffer from painful mouth sores. New evidence suggests immunonutrition could help manage these symp…
Frontiers Jul 28, 2026
Postoperative radiotherapy reduces local and peristomal recurrence rates in laryngeal cancer patients with preoperative tracheotomy
ENT (Otolaryngology) Meta-analysis
Postoperative radiotherapy reduces local and peristomal recurrence rates in laryngeal cancer patients with preoperative tracheotomy Radiotherapy May Lower Recurrence Risk After Laryngectomy for Cancer
This meta-analysis of 4339 patients evaluates the impact of postoperative radiotherapy (PORT) on recurrence rates following total laryngecto…
Postoperative radiotherapy may lower the risk of cancer returning in the throat area for patients who had a tracheotomy before surgery.
Jul 25, 2026
Zygomatic implants provide high survival rates for maxillary reconstruction in head and neck cancer patients
ENT (Otolaryngology) Meta-analysis
Zygomatic implants provide high survival rates for maxillary reconstruction in head and neck cancer patients Zygomatic implants show high survival for head and neck cancer
This systematic review and meta-analysis of 294 patients with extensive maxillary defects found a 97% overall implant survival rate. The ana…
New data shows zygomatic implants have a 97% survival rate, offering a reliable way to restore jaw function after cancer surgery.
Jul 25, 2026
Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
ENT (Otolaryngology) Meta-analysis
Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC Treatment Naive Patients Show Better Survival with Camrelizumab and Apatinib
This meta-analysis evaluates the efficacy of camrelizumab plus apatinib for advanced or metastatic esophageal squamous cell carcinoma. The a…
Patients with advanced esophageal cancer who have not had prior treatment may see better survival rates when using a combination of camreliz…
Jul 25, 2026
Sintilimab may trigger autoimmune GFAP astrocytopathy in esophageal squamous cell carcinoma patients
Allergy & Immunology Sys. Review
Sintilimab may trigger autoimmune GFAP astrocytopathy in esophageal squamous cell carcinoma patients New cancer treatment may cause rare brain inflammation in patients
This case report and literature review describes a patient with advanced esophageal squamous cell carcinoma who developed autoimmune GFAP as…
A new type of immunotherapy for esophageal cancer can trigger a rare brain condition, requiring doctors to watch for early signs of neurolog…
Frontiers Jul 25, 2026
HPV shows strong association with oropharyngeal SCC while other oncogenic viruses show limited evidence
Oncology Meta-analysis
HPV shows strong association with oropharyngeal SCC while other oncogenic viruses show limited evidence Viruses linked to oral and throat cancers in new review
This systematic review examines the role of various oncogenic viruses in oral and oropharyngeal squamous cell carcinomas. It identifies a co…
A strong link between HPV and throat cancer is confirmed, while other viruses show less clear evidence of causing cancer.
Frontiers Jul 23, 2026
Prophylactic PEG tube placement improves nutritional status and reduces hospitalizations for head and neck cancer patients
Oncology Meta-analysis
Prophylactic PEG tube placement improves nutritional status and reduces hospitalizations for head and neck cancer patients Proactive Feeding Tubes May Improve Support for Head and Neck Cancer
This meta-analysis of 1279 patients evaluates prophylactic versus reactive percutaneous endoscopic gastrostomy (PEG) tubes in head and neck …
Early placement of feeding tubes may improve nutritional stability and reduce hospital stays for patients undergoing head and neck cancer tr…
Jul 15, 2026
Neoadjuvant chemoimmunotherapy improves pathological response and surgical rates in resectable esophageal squamous cell carcinoma
Allergy & Immunology Meta-analysis
Neoadjuvant chemoimmunotherapy improves pathological response and surgical rates in resectable esophageal squamous cell carcinoma Immune therapy shows promise for esophageal squamous cell carcinoma
This meta-analysis of randomized controlled trials involving 1070 patients found that neoadjuvant chemoimmunotherapy (NIC) significantly imp…
Adding immune checkpoint inhibitors to chemotherapy before surgery significantly improves tumor response rates in patients with esophageal c…
Frontiers Jul 10, 2026
Hyperspectral imaging shows strong diagnostic performance for oral cancer detection in scoping review
Oncology Sys. Review
Hyperspectral imaging shows strong diagnostic performance for oral cancer detection in scoping review Hyperspectral imaging shows promise for detecting oral cancer
This scoping review of 15 studies found that hyperspectral imaging (HSI) demonstrates strong diagnostic performance for detecting and charac…
A new review finds hyperspectral imaging can spot oral cancer with high accuracy, offering a non-contact alternative for margin assessment.
Frontiers Jul 9, 2026
High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
Oncology Meta-analysis
High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors High levels of PTTG1 protein linked to worse cancer outcomes
This meta-analysis of 22 studies from 21 articles analyzed the prognostic value of PTTG1 expression across multiple solid tumors. High PTTG1…
A review of 22 studies shows that high levels of the PTTG1 protein are linked to shorter survival times in several types of solid tumors.
Frontiers Jun 27, 2026
Zinc supplementation shows potential in reducing severe radiation-induced oral mucositis in head and neck cancer patients
Oncology Meta-analysis
Zinc supplementation shows potential in reducing severe radiation-induced oral mucositis in head and neck cancer patients Zinc Mouthwash May Reduce Severe Mouth Sores From Radiation
Researchers evaluated the impact of topical and systemic zinc on the incidence of severe radiation-induced oral mucositis in head and neck c…
A new analysis suggests zinc mouthwash may cut the risk of severe mouth sores from radiation by 84%.
Jun 26, 2026
Oral diseases stem from disrupted host-microbiome-immune balance, narrative review argues
Gastroenterology Sys. Review
Oral diseases stem from disrupted host-microbiome-immune balance, narrative review argues New research explores how oral bacteria drive gum disease
This narrative review argues that periodontitis, dental caries, and oral squamous cell carcinoma should be understood as disorders of host-m…
Oral health depends on a delicate balance between your immune system, tissue barriers, and the trillions of microbes living in your mouth.
Frontiers Jun 22, 2026

Questions about Head and Neck Squamous Cell Carcinoma

What is the objective response rate for becotatug vedotin in recurrent head and neck cancer?

Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.

Full answer →
Does reducing radiotherapy doses lower toxicity in head and neck squamous cell carcinoma?

Yes, reducing radiotherapy doses through margin reduction, adaptive planning, or proton therapy can lower acute and late toxicity in head and neck squamous cell carcinoma, though clinical benefits may be modest in unselected patients.

Full answer →
What are the risks of HPV-associated head and neck squamous cell carcinoma?

HPV-associated head and neck squamous cell carcinoma risks include persistent HPV infection (especially HPV16), distinct metabolic changes, and epigenetic dysregulation, but these tumors often have a better prognosis than HPV-negative cancers.

Full answer →
How do therapeutic cancer vaccines work for head and neck squamous cell carcinoma?

Therapeutic cancer vaccines train the immune system to recognize and attack HNSCC cells by targeting tumor-specific antigens, but achieving durable responses remains challenging.

Full answer →

All Head and Neck Squamous Cell Carcinoma Articles